Jacqueline A French
Affiliation: New York University School of Medicine
- Effects of marketed antiepileptic drugs and placebo in the human photosensitivity screening protocolJacqueline A French
Department of Neurology, NYU Langone Medical Center, 223 E 34th Street, New York, NY, 10016, USA
Neurotherapeutics 11:412-8. 2014..We cannot confirm the ability of the photosensitivity trial to detect the narrow-spectrum AED CBZ in our design. The novel outpatient study design is feasible and is expected to reduce costs compared with previous methodology...
- Development of new treatment approaches for epilepsy: unmet needs and opportunitiesJacqueline A French
Department of Neurology, NYU School of Medicine, New York, New York 10016, USA
Epilepsia 54:3-12. 2013..However, the group acknowledged that disease-modifying therapies (given after the first seizure or after the development of epilepsy) would be easier to study than AEG therapies...
- Designing a new proof-of-principle trial for treatment of partial seizures to demonstrate efficacy with minimal sample size and duration-a case studyJacqueline A French
NYU Comprehensive Epilepsy Center, Department of Neurology, New York University, 223 East 34th Street, New York, NY 10016, USA
Epilepsy Res 106:230-6. 2013..These modeling results indicate that the efficacy of an antiepileptic drug can be demonstrated in a relatively short period of time with a reasonable sample size...
- Antiepileptic drug treatment: new drugs and new strategiesJacqueline A French
Continuum (Minneap Minn) 19:643-55. 2013..Special consideration must be given to populations such as women, older adults, patients with other medical comorbidities, and patients who are newly diagnosed...
- Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305Jacqueline A French
NYU Comprehensive Epilepsy Center, New York, New York 10016, USA
Epilepsia 54:117-25. 2013..To assess the efficacy and safety of once-daily doses of perampanel 8 and 12 mg when added to 1-3 concomitantly administered, approved antiepileptic drugs (AEDs) in patients with uncontrolled partial-onset seizures...
- Analysis of three lamotrigine extended-release clinical trials: comparison of pragmatic ITT and LOCF methodologiesJacqueline A French
NYU Comprehensive Epilepsy Center, 223 E 34th St, New York, NY 10016, United States
Epilepsy Res 101:141-7. 2012..We propose that the P-ITT may be a simpler, more informative method for evaluating the effectiveness of a drug, especially in comparison to another active drug(s)...
- Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304Jacqueline A French
NYU Comprehensive Epilepsy Center, New York, NY, USA
Neurology 79:589-96. 2012....
- Lamotrigine XR conversion to monotherapy: first study using a historical control groupJacqueline A French
NYU Comprehensive Epilepsy Center, New York, NY 10016, USA
Neurotherapeutics 9:176-84. 2012..LTG XR (250 mg or 300 mg once daily) is effective for conversion-to-monotherapy treatment of partial seizures in patients ≥13 years old...
- Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control studyJason F Okulicz
Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
AIDS Res Ther 8:18. 2011..abstract:..
- Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsyJ A French
NYU Comprehensive Epilepsy Center, 223 East 34th Street, New York, NY 10016, USA
Neurology 76:1555-63. 2011....
- Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trialJ A French
NYU Comprehensive Epilepsy Center, New York, NY 10016, USA
Neurology 75:519-25. 2010....
- Historical control monotherapy design in the treatment of epilepsyJacqueline A French
Department of Neurology, New York University, New York, New York, USA
Epilepsia 51:1936-43. 2010..Such an approach reduces patient risk that would result from exposure to pseudo-placebo. In this article, we present the data submitted to the FDA to justify a historical control...
- Rational polytherapyJacqueline A French
New York University School of Medicine, New York, New York, USA
Epilepsia 50:63-8. 2009..However, more animal and human research is needed, with attention to the effects of various combinations on both toxicity and seizure control...
- Clinical practice. Initial management of epilepsyJacqueline A French
Department of Neurology, New York University School of Medicine, New York, USA
N Engl J Med 359:166-76. 2008
- Invited article: comparative effectiveness research, evidence-based medicine, and the AANJacqueline A French
New York University Comprehensive Epilepsy Center, New York, NY, USA
Neurology 75:562-7. 2010..The neurology community must help inform the process of CER to ensure the highest-quality research, which in turn will result in the most valid outcomes...
- Long-term behavioral, electrophysiological, and neurochemical monitoring of the safety of an experimental antiepileptic implant, the muscimol-delivering Subdural Pharmacotherapy Device in monkeysNandor Ludvig
Department of Neurology, Comprehensive Epilepsy Center, NYU Langone Medical Center School of Medicine, New York, New York 10016, USA
J Neurosurg 117:162-75. 2012....
- Periodic transmeningeal muscimol maintains its antiepileptic efficacy over three weeks without inducing tolerance, in ratsHai M Tang
NYU Comprehensive Epilepsy Center, NYU School of Medicine Langone Medical Center, 223 East 34th Street, New York, NY, USA
Neurosci Lett 494:135-8. 2011..These results suggest that periodic transmeningeal administrations of a relatively low concentration of muscimol into the neocortex over three weeks do not induce tolerance to the localized antiepileptic effects of this drug...
- Transmeningeal muscimol can prevent focal EEG seizures in the rat neocortex without stopping multineuronal activity in the treated areaNandor Ludvig
NYU Comprehensive Epilepsy Center, NYU School of Medicine Langone Medical Center, New York, NY 10016, USA
Brain Res 1385:182-91. 2011....
- Seizure-free outcome in randomized add-on trials of the new antiepileptic drugsDeana M Gazzola
Hospital of the University of Pennsylvania, Department of Neurology, Philadelphia, Pennsylvania 19104, USA
Epilepsia 48:1303-7. 2007..The goal of this study is to (1) provide clinically useful, previously unpublished comparative analyses of seizure-freedom rates for newer antiepileptic drugs (AEDs), and (2) recommend a standard for data presentation and analysis...
- An implantable triple-function device for local drug delivery, cerebrospinal fluid removal and EEG recording in the cranial subdural/subarachnoid space of primatesNandor Ludvig
NYU Comprehensive Epilepsy Center, New York University School of Medicine NYU Langone Medical Center, 223 East 34th Street, New York, NY 10016, USA
J Neurosci Methods 203:275-83. 2012....
- Likelihood of seizure remission in an adult population with refractory epilepsyBrian C Callaghan
Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA
Ann Neurol 62:382-9. 2007..We aimed to determine the likelihood of remission and its clinical predictors in adult patients meeting a strict definition of refractory epilepsy. We also wanted to investigate the influence of treatment regimen on remission...
- Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalinDeborah E Briggs
Department of Neurology, University of Pennsylvania Health System, Philadelphia, PA, United States
Epilepsy Res 82:86-92. 2008..To determine whether pregabalin reduces SGTC seizures in clinically refractory epilepsy...
- Effects of intermittent levetiracetam dosing in a patient with refractory daily seizuresDaniel Friedman
Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104 4283, USA
Neurology 66:590-1. 2006..These results suggest a useful treatment strategy for patients with refractory epilepsy who have developed resistance to AEDs...
- Guidelines for new antiepileptic drug evaluationJohn D Hixson
Department of Neurology, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Rev Neurol Dis 1:S18-26. 2004..Neurologists are encouraged to integrate the AAN guidelines with clinical experience, opinion, and other considerations of special populations until an exhaustive set of guidelines is available for a wide variety of seizure types...
- Suicidal ideation and behavior screening in intractable focal epilepsy eligible for drug trialsDale C Hesdorffer
GH Sergievsky Center and Department of Epidemiology, Columbia University, New York, New York 10032, USA
Epilepsia 54:879-87. 2013..This was done to determine which instrument was optimal for use in epilepsy...
- Clinical trials for therapeutic assessment of antiepileptic drugs in the 21st century: obstacles and solutionsDaniel Friedman
NYU Comprehensive Epilepsy Center, Department of Neurology, New York University, New York, NY 10016, USA
Lancet Neurol 11:827-34. 2012..Novel trial designs, such as time-to-event adjunctive therapy and historical-control monotherapy, might be more acceptable to patients and their doctors because they restrict exposure to placebo or ineffective treatments...
- Comparison of the antiepileptic properties of transmeningeally delivered muscimol, lidocaine, midazolam, pentobarbital and GABA, in ratsShirn L Baptiste
NYU Comprehensive Epilepsy Center, New York University School of Medicine, NYU Langone Medical Center, New York 10016, USA
Neurosci Lett 469:421-4. 2010..These results suggest that when used at low concentration muscimol was the best of the five drugs for transmeningeal pharmacotherapy trials for focal neocortical epilepsy...
- Refractory epilepsy: clinical overviewJacqueline A French
Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
Epilepsia 48:3-7. 2007....
- Fear sensitivity and the psychological profile of patients with psychogenic nonepileptic seizuresJohn D Hixson
Department of Neurology, University of California, San Francisco, CA 94143 0114, USA
Epilepsy Behav 9:587-92. 2006..This finding may reflect an elevated internal "setpoint" for appraising the intensity of emotional settings...
- Common data elements in epilepsy research: development and implementation of the NINDS epilepsy CDE projectDavid W Loring
Department of Neurology, Emory University, Atlanta, Georgia, USA
Epilepsia 52:1186-91. 2011..This article describes the NINDS CDE Initiative, the process used in developing Epilepsy CDEs, and the benefits of CDEs for the clinical investigator and NINDS...
- Hospital-onset seizures: an inpatient studyMadeline C Fields
Department of Neurology, Mount Sinai School of Medicine, One Gustave L Levy Pl, New York, NY 10029, USA
JAMA Neurol 70:360-4. 2013..To describe demographic and clinical characteristics of patients with hospital-onset seizure (HOS) and to explore current practices in their management...
- Can evidence-based guidelines and clinical trials tell us how to treat patients?Jacqueline A French
Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Epilepsia 48:1264-7. 2007
- First-choice drug for newly diagnosed epilepsyJacqueline A French
Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA
Lancet 369:970-1. 2007
- Levetiracetam safety profiles and tolerability in epilepsy patientsDeborah E Briggs
Department of Neurology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104 4283, USA
Expert Opin Drug Saf 3:415-24. 2004..Adjustments in dosing are required for decreases in renal clearance...
- Electrical stimulation of the anterior nucleus of the thalamus for the treatment of intractable epilepsyJohn F Kerrigan
Department of Neurology, Barrow Neurological Institute, St Joseph s Hospital and Medical Center, Phoenix, Arizona, USA
Epilepsia 45:346-54. 2004....
- Neurosyphilis and status epilepticus: case report and literature reviewBeau M Ances
Department of Neurology, University of Pennsylvania Medical Center, 3400 Spruce Street, Philadelphia, PA 19104, USA
Epilepsy Res 59:67-70. 2004..Neurosyphilis should be considered in the differential diagnosis of patients presenting with status epilepticus...
- Guidelines--are they useful?Elinor Ben-Menachem
Department of Clinical Neuroscience, Sahlgrenska Academy, Goteborg University, Goteborg, Sweden
Epilepsia 47:62-4. 2006..Although guidelines may not answer all questions it is critical that clinicians using them consider the available evidence, as well as the quality of the evidence, when incorporating the information in their decision making...
- Postmarketing surveillance of new antiepileptic drugs: the tribulations of trialsJacqueline A French
Epilepsia 43:951-5. 2002
- A workshop on antiepileptic drug monotherapy indicationsJacqueline A French
The Neurological Institute, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Epilepsia 43:3-27. 2002
- Evaluation of carisbamate, a novel antiepileptic drug, in photosensitive patients: an exploratory, placebo-controlled studyDorothée G A Kasteleijn Nolst Trenité
University La Sapienza II, Via Vitorchiano 81, 00189 Roma, Italy
Epilepsy Res 74:193-200. 2007....
- VNS Therapy versus the latest antiepileptic drugElinor Ben-Menachem
Department of Clinical Neuroscience, Sahlgren University Hospital, Sweden
Epileptic Disord 7:S22-6. 2005....
- Is refractory epilepsy preventable?Santiago Arroyo
Epilepsy Unit, Hospital Clinic i Provincial, Barcelona, Spain
Epilepsia 43:437-44. 2002..The early initiation of aggressive therapy may improve outcome and overall quality of life...
- Antiepileptic drugs for the elderly: using the old to focus on the newJacqueline A French
Neurology 64:1834-5. 2005
- October 2002: 27-year-old female with epilepsyZissimos Mourelatos
Division of Neuropathology, Department of Pathology, University of Pennsylvania Medical Center, Philadelphia, USA
Brain Pathol 13:233-4, 239. 2003..The treatment of choice is functionally complete hemispherectomy with complete disconnection of the frontal and occipital lobes...
- Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsyChristian Otoul
UCB Pharma, Braine l Alleud, Belgium
Clin Neuropharmacol 28:72-8. 2005..These meta-analyses give only short-term efficacy and safety data. Comparative clinical trials and long-term studies of these agents are needed to confirm these findings...
- Role of levetiracetam in the treatment of epilepsyMartin J Brodie
Epilepsy Unit, Division of Cardiovascular and Medical Sciences, Western Infirmary, Glasgow, Scotland, United Kingdom
Epileptic Disord 5:S65-72. 2003..Levetiracetam has specific characteristics that make it an optimal choice for many patient populations...
- A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse eventsAndres M Kanner
Department of Neurological Sciences, Rush Presbyterian St Luke s Medical Center, Rush Medical College, 1653 West Congress Parkway, Chicago, IL 60612, USA
Epilepsy Behav 4:548-52. 2003....
- Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy SocietyJacqueline A French
Neurological Institute, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Epilepsia 45:410-23. 2004....
- New antiepileptic drugs--discovery, development, and updateRoger J Porter
Neurotherapeutics 4:2-3. 2007
- Active control trials for epilepsy: avoiding bias in head-to-head trialsJacqueline A French
Neurology 66:1294-5. 2006